Today, we talk about a paper that showed impressive neurologically intact survival for all-rhythms presenting in cardiac arrest, both OHCA and IHCA. It uses a new set of strategies and technologies called CARL.
The Paper
- Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body: A Multicenter, Prospective Observational Study
- Supplemental Material
Review Paper
Freidhelm Beyersdorf
COI
Dr. Beyersdorf is the founder and a current shareholder of Resuscitech, the parent company of the CARL System
CARL Circuit
Eight Differences of the CARL Strategy
- Cytoprotective Perfusate Prime (see below)
- Pulsatile Flow – using 2 pumps in the circuit
- Multi-Organ Repair Strategy
- High-Flow/High Pressure Strategy
- Immediate Hypothermia to 32-33 C
- Real-Time Monitoring
- Portable System
- Mandatory Distal-Limb Perfusion
Priming Perfusate
Some of the Multi-Organ Repair Strategy

- See the supplemental material above for the whole strategy
Real-Time Monitoring
Real-time monitoring of hemodynamic parameters (cardiac output, heart rate, and blood pressure), venous and arterial blood gases (pO2 and pH), electrolytes (calcium, potassium, and sodium), and venous blood temperature was implemented to achieve the necessary personalized treatment for multiorgan repair (10.3390/jcm13010056)
Additional New Information
More on EMCrit
Now on to the Wee
- EMCrit Shadowboxing Case 9 – Spinal Cord Injury? - April 24, 2025
- EMCrit 399 – Serotonin Syndrome (SS) and Neuroleptic Malignant Syndrome (NMS) – Primer Episode - April 17, 2025
- 1:1 Nursing Podcast – Episode 0 – The Introduction - April 14, 2025
Last two episodes have been over the top great. I am intrigued by the priming solution and pulsatile flow; makes sense. Planning a deep dive into this solution, cant wait to read the paper.
Great post! Block Blast Unblocked